BIO.DE Biotest AG €42.20 (XETRA) 29 Jan 2026: Oversold bounce as tactical entry
Biotest AG (BIO.DE) closed on XETRA in Germany at €42.20 on 29 Jan 2026, signaling a small pullback after a recent run near its year high. The setup reads like an oversold bounce: volume at 175.00 shares and relative volume 1.36 suggest active interest in a thin book. Traders watching BIO.DE stock can consider short-term entries while monitoring fundamentals such as EPS -0.63 and PE -66.98. Meyka AI’s research flags a mixed picture of solid liquidity and stretched valuation, so we frame this as a tactical trade, not a long-term buy thesis
BIO.DE stock: Market snapshot and key numbers
BIO.DE stock traded at €42.20 on XETRA, down €0.40 or 0.94% on the session. Daily range was €42.20–€43.00, year high €43.20 and year low €40.40. Market cap stood at 1,396,870,640.00 EUR with 33,101,200.00 shares outstanding and volume 175.00 versus average 129.00.
BIO.DE stock: Why an oversold bounce setup is emerging
Price sits just below the 50-day average €42.54, a slight discount that can attract short-term buyers. Relative volume 1.36 indicates above-average trading on low absolute volume, fitting an oversold bounce profile. The stock’s short-term pullback of 0.94% on 29 Jan 2026 creates a low-risk zone for tactical entries with tight stops near €40.40.
BIO.DE stock: Fundamentals, valuation and risks
Biotest reports EPS -0.63 and a negative trailing PE of -66.98, reflecting recent losses and cyclical pressure in biotech. Debt to equity is 1.31 and current ratio 4.93, showing ample short-term liquidity but meaningful leverage. Free cash flow per share is -1.87, and margins remain thin, so fundamentals support caution for long-term investors.
Meyka AI rates BIO.DE with a score out of 100
Meyka AI rates BIO.DE with a score of 66.93 out of 100 (Grade B, HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamentals. These grades are model outputs and are not financial advice and not guarantees of performance.
BIO.DE stock: Price targets and Meyka AI forecast
Meyka AI’s forecast model projects a yearly price of €42.05, a 3-year level of €41.45, and a 5-year level of €40.86. Compared with the current €42.20, the one-year model implies -0.35% downside. Practical price targets for traders: conservative target €38.00 (-10.00%) and optimistic target €50.00 (+18.48%). Forecasts are model-based projections and not guarantees.
BIO.DE stock: Tactical trading plan for an oversold bounce
For traders we recommend a staged entry around €42.00–€42.50 with a stop-loss near €39.75 and a first take-profit at €46.00. Position sizing should limit risk to 1.0%–2.0% of portfolio value. Monitor catalysts: Q4 updates, plasma supply notes, and the next material announcement. Use tight risk controls given BIO.DE’s negative cash flow and sector volatility.
Final Thoughts
Biotest AG (BIO.DE) offers a classic oversold bounce trade on XETRA after closing at €42.20 on 29 Jan 2026. Short-term setups look reasonable because price sits just below the 50-day average €42.54 and relative volume 1.36 shows buyer interest. Fundamentals remain mixed: EPS -0.63, negative free cash flow per share -1.87, and debt to equity 1.31 argue for caution. Meyka AI’s forecast model projects a one-year price of €42.05, implying marginal downside of -0.35% versus the current price; the model also shows gradual mean reversion in the next three to five years. For tactical traders we outline clear entry and stop levels and two price targets: conservative €38.00 and optimistic €50.00. Remember, Meyka AI is an AI-powered market analysis platform and these forecasts are model-based projections and not guarantees. Use tight risk management and watch sector flows in Healthcare when positioning in BIO.DE stock.
FAQs
Is BIO.DE stock a buy after the 29 Jan 2026 pullback?
BIO.DE stock can be a tactical buy for short-term traders on an oversold bounce, but fundamentals show negative EPS and cash flow. Use a tight stop-loss and limit position size; long-term investors should wait for clearer profit recovery signals.
What are the main risks for BIO.DE stock right now?
Main risks include negative free cash flow per share -1.87, EPS -0.63, leverage with debt to equity 1.31, and biotech sector volatility. Operational updates or plasma supply disruptions could widen downside quickly.
How does Meyka AI forecast affect a trading plan for BIO.DE stock?
Meyka AI’s forecast model projects €42.05 for one year, near current price, which suggests limited upside from here. Use the forecast as one input among technicals and fundamentals, not as a sole decision driver.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
